Novartis and Monte Rosa Forge $2.2B Molecular Glue Partnership for Autoimmune Treatments

Novartis and Monte Rosa Therapeutics have forged a groundbreaking partnership, with the Swiss pharma giant committing to an initial $150 million in a deal that could total up to $2.2 billion. This collaboration focuses on the development and commercialization of molecular glue degraders, particularly MRT-6160, which targets the VAV1 protein associated with autoimmune diseases[1][3]. Novartis will lead the clinical development from Phase II onwards, while Monte Rosa completes Phase I, with future profit-sharing from US sales[2][3]. This deal aligns with a broader industry trend toward molecular glue technology, mirroring similar interests from companies like Roche and Takeda[1].